Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Colorectal Cancer

Breast Cancer

Gastrointestinal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Colorectal Cancer

Investigators Test Breakthrough-Designated Triplet in First-Line CRC

Investigators hope to answer a potentially paradigm-changing question in the phase II ANCHOR-CRC study (NCT03693170) of BRAF V600E–mutant colorectal cancer (CRC): Can the benefit observed with a targeted triplet in latestage disease extend...
Read More >>

Molecular Testing for Colon Cancer Falls Far Short of the Guidelines

Role of Immunotherapy Agents Grows in Metastatic Colorectal Cancer

Expert Highlights Immunotherapy Combo Strategies in Relapsed/Refractory CRC

FDA Grants Priority Review to Encorafenib/Cetuximab Combo for BRAF+ mCRC

Genomic Era Trials Drive Discovery

View More Stories >>

View Conference Coverage

2019 San Antonio Breast Cancer Symposium

2019 ASH Annual Meeting

2019 International Congress of the Society for Melanoma Research

2019 State of the Science Summit on Genitourinary Cancers in Nashville

2019 State of the Science Summit on Hematologic Malignancies in Chicago

Dr. Lockhart on Strategies for Targeting the RAS/RAF/MEK/ERK Pathway in CRC

Dr Weinberg on Varying Treatment Options in Metastatic Colorectal Cancer

Dr. Vulfovich on Molecular Testing in Colorectal Cancer

Dr. Lockhart on Next Steps for Regorafenib and TAS-102 in mCRC

Dr. Vulfovich on Broad Molecular Profiling in mCRC

Dr. Benson on Treatment for Patients With Resectable Colorectal Cancer

OncLive houses thousands of videos that provide updates and information.
See more Videos

Future Directions in I/O Therapy for mCRC

Immunotherapy in CRC

New Therapy Options for BRAF-Mutated mCRC

Management of Colorectal Cancer Metastases

TRIBE-2: FOLFOX or FOLFIRI With Bevacizumab in mCRC

OncLive houses thousands of videos that provide updates and information.
See more Videos

Novel Therapies for BRAF+ Colorectal Cancer

Treating BRAF+ Colorectal Cancer

Targeting BRAF and MEK in Colorectal Cancer

Ongoing Treatment & Approach Advancements in mCRC

Combination Therapy Updates from ASCO 2019

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Treatment Goals in Refractory mCRC

$Treatment Goals in Refractory mCRC$
Tanios Bekaii-Saab, MD, FACP, Andrea Cercek, MD, and Zev A. Wainberg, MD, provide insight to the treatment goals for patients with refractory metastatic colorectal cancer.

View Now

Therapeutic Strategies in Metastatic Colorectal Cancer

Recent advances in the treatment of metastatic colorectal cancer (mCRC) have improved survival. However, many questions remain. Led by John L. Marshall, MD, panelists Tanios Bekaii-Saab, MD; Johanna Bendell, MD; Richard Kim, MD; and Charles S. Fuchs, MD, MPH, discuss strategies and approaches to managing mCRC, including the latest research and how it may influence clinical practice.

View Now

Featured Video

Dr. Esteva on the Future of Biosimilars in Breast Cancer

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now

FDA Approvals in Urothelial Cancer and GIST, Promising Data in Urothelial Carcinoma, and More